The Global Fever

Tech

AI Funding Keeps Flowing as Isomorphic, DeepSeek and ByteDance Line Up Billions

Isomorphic Labs raised $5 billion, DeepSeek is reported to have raised about $15 billion and ByteDance plans a $6 billion buyback, even as AI stocks fell.

Wasif Mumtaz

Founder and Editor · November 23, 2026 · 6 min read

Blue fiber optic light lines streaking across a dark background
Photo: Magnific

AI funding kept flowing this month even as AI-linked shares sold off. Isomorphic Labs, the Google DeepMind spinout, announced a $5 billion Series C on November 17. DeepSeek is reported to have raised about 100 billion yuan, roughly $15 billion, in a second outside round. ByteDance is planning a buyback of up to $6 billion at a valuation of about $400 billion, according to The Information.

The three deals are confirmed to different degrees. Isomorphic announced its round itself. DeepSeek's comes from anonymous sources, and the company has not confirmed it. ByteDance's rests on a single report that cites a shareholder letter. Taken together, they show private investors still committing large sums to AI companies while public markets reprice the sector.

Isomorphic Labs raises $5 billion for AI drug discovery

Isomorphic Labs announced the Series C on Tuesday, November 17. Greenoaks and Sequoia Capital co-led the round, according to pharmaphorum and City AM. Andreessen Horowitz joined as a new investor, alongside Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

The London-based company was spun out of Google DeepMind in 2021 and is led by Sir Demis Hassabis. The round came about six months after a $2.1 billion Series B in May, which Thrive Capital led, according to the company's own release. Disclosed external funding now totals roughly $7.7 billion since 2025, pharmaphorum reports.

Trade press has described the raise as the largest venture round in biotech history. That label comes from industry outlets rather than an official tally, so treat it as a characterization. Isomorphic has not disclosed a valuation. City AM notes that earlier reports pointed to a target of up to $50 billion, up from about $17.5 billion previously.

The proceeds are meant to build out its drug design engine, called IsoDDE, and to scale its internal and partnered pipeline. The company works with Johnson & Johnson, Novartis and Eli Lilly. No drug candidate has entered human trials. City AM describes the company as in late-stage preclinical development, and pharmaphorum reports positive preclinical results in oncology and immunology.

Hassabis said: "Our drug design engine is generating molecules with unprecedented precision and speed." UK AI minister Kanishka Narayan called it "one of the biggest Series C rounds in UK tech history," and pointed to the Sovereign AI Fund's follow-on investment.

DeepSeek's reported round of about 100 billion yuan

Reuters reported on October 22, citing four people with knowledge of the matter, that DeepSeek had raised about 100 billion yuan, or $14.98 billion, in its latest round. Bloomberg had reported a similar $15 billion figure. DeepSeek could not be reached for comment, and the company has not confirmed the round.

CATL and Tencent, both existing shareholders, were among the biggest investors, Reuters said. Chipmaker GigaDevice, Meituan and automaker Geely were also named, and more than 15 investors took part in total. Sources told Reuters the company was valued at 500 billion yuan before the new money.

The target grew during talks. Bloomberg reported that it rose from 50 billion yuan to 80 billion yuan and ended near 100 billion yuan. Reuters cautioned that the final details and investor list could still change, and said the round was expected to close within days. A secondary report attributed to The Information gave a higher figure of 105.5 billion yuan, so the exact total depends on the source.

This is DeepSeek's second outside round this year. Reuters says the Hangzhou-based lab raised $7.4 billion in June in its first. Reuters also reported in September that DeepSeek aimed to start an IPO process this year, with CITIC Securities preparing a possible STAR Market listing.

ByteDance plans a $6 billion buyback at about a $400 billion valuation

The Information reported on November 13, citing a letter to shareholders, that ByteDance plans to buy back up to $6 billion of shares from existing investors at a valuation of about $400 billion. We read the report through investingLive, a smaller outlet, and found no confirmation from Reuters or Bloomberg. Treat the figures as reported, not announced.

The valuation is about 20% above the previous buyback a year earlier, which investingLive puts at about $330 billion. Earlier repurchases were reportedly valued at about $268 billion in late 2023 and about $300 billion a year after that.

A minority-stake deal late last year reportedly valued ByteDance at about $480 billion, so the buyback price sits below that mark. A buyback lets existing shareholders sell stock back to the company, and ByteDance receives no new capital from it. It is a different kind of deal from the two funding rounds, but it still sets a price on one of the largest private companies in the world.

Why AI funding is holding up while AI stocks fall

Public markets have been under heavy pressure. On November 19 the S&P 500 fell 2% to 7,175.83, its sixth straight loss, and the Nasdaq Composite dropped 2.3%. The next day Japan's Nikkei fell 5.1%, South Korea's Kospi 5.2% and Taiwan's Taiex 6.2%. Our report on the global AI stock selloff has the full picture.

Anthropic's Nasdaq debut on November 19 raised about $81.3 billion, the largest IPO on record, as we covered in our Anthropic IPO report. Its shares closed the first day up 17.1% even as the major indexes fell. Demand for AI exposure had not disappeared; it was being priced more cautiously elsewhere.

Private rounds and public stocks do not move together day to day. A private valuation is set in a negotiation between a company and a small group of investors, and deals like these take months to assemble. DeepSeek's round had been in the works since mid-year, long before the latest selloff.

That does not make private AI money immune to a downturn. If public valuations stay lower, later rounds, listings and buybacks may be priced differently. For now, the backers in these deals include sovereign-linked funds such as the UK Sovereign AI Fund, MGX and Temasek, strategic investors such as Tencent and CATL, and venture firms such as Sequoia and Andreessen Horowitz. Each has its own reasons and time horizon.

What to watch next in AI funding

For DeepSeek, the first question is whether the round closes near 100 billion yuan and whether the company or its investors confirm it. A confirmed valuation and investor list would settle the discrepancy between the reported figures. Any formal step toward an IPO would be the next marker.

For Isomorphic, the test is the clinic. The company says the proceeds will move its programs toward human trials, and the sources reviewed give no firm date. The first candidate to enter a trial would show how its preclinical results translate into patients.

For ByteDance, watch for confirmation from the company or a major outlet, and for how many shareholders choose to sell. Across all three, the broader backdrop matters: if equity markets stay weak, the next round of private pricing will show whether investors keep paying these multiples.

Frequently asked questions

How much did Isomorphic Labs raise?

Isomorphic Labs announced a $5 billion Series C on November 17, co-led by Greenoaks and Sequoia Capital. It follows a $2.1 billion Series B from May. The company has not disclosed a valuation.

Has DeepSeek confirmed its funding round?

No. Reuters and Bloomberg reported a raise of about 100 billion yuan, roughly $15 billion, citing people familiar with the matter. DeepSeek has not confirmed it, and Reuters said details could still change.

What is ByteDance's reported buyback?

The Information reported that ByteDance plans to repurchase up to $6 billion of shares from existing investors at a valuation of about $400 billion. That is roughly 20% above last year's buyback. We could not find confirmation from a major outlet.

Why is AI funding continuing when AI stocks are falling?

Private deals are negotiated over months and priced by a small group of investors, so they do not react to daily market moves. If public valuations stay lower, future private pricing could change.

Is Isomorphic's round the largest in biotech history?

Trade press has described it that way, but no official ranking backs the claim. Treat it as a characterization from industry outlets rather than a verified record.

ShareXLinkedInWhatsApp

Sources

Related stories

Tech

Anthropic IPO Process: Reuters Details Project Lantern Banker Complaints

Reuters reports that Anthropic's IPO, code-named Project Lantern, came with a compressed timeline, rushed approvals and unusual limits on bankers. Anthropic declined to comment.

Tech

AI Server Prices: Dell, HPE, Lenovo and Supermicro Reportedly Seek Up to 45% More

Dell, HPE, Lenovo and Supermicro are reportedly asking AI server buyers for up to 45% more months after signing, citing memory costs, the Financial Times says.

Tech

Isomorphic Labs Raises $5 Billion in Biotech's Largest Venture Round

Isomorphic Labs announced a $5 billion Series C on November 17, co-led by Greenoaks and Sequoia. Reports call it the largest venture round in biotech history, six months after a $2.1 billion Series B.